Parechovirus A Infections in Healthy Australian Children During the First 2 Years of Life: A Community-based Longitudinal Birth Cohort Study

Claire Y T Wang, Robert S Ware, Stephen B Lambert, Lebogang P Mhango, Sarah Tozer, Rebecca Day, Keith Grimwood, Seweryn Bialasiewicz, Claire Y T Wang, Robert S Ware, Stephen B Lambert, Lebogang P Mhango, Sarah Tozer, Rebecca Day, Keith Grimwood, Seweryn Bialasiewicz

Abstract

Background: Hospital-based studies identify parechovirus (PeV), primarily PeV-A3, as an important cause of severe infections in young children. However, few community-based studies have been published and the true PeV infection burden is unknown. We investigated PeV epidemiology in healthy children participating in a community-based, longitudinal birth cohort study.

Methods: Australian children (n = 158) enrolled in the Observational Research in Childhood Infectious Diseases (ORChID) study were followed from birth until their second birthday. Weekly stool and nasal swabs and daily symptom diaries were collected. Swabs were tested for PeV by reverse-transcription polymerase chain reaction and genotypes determined by subgenomic sequencing. Incidence rate, infection characteristics, clinical associations, and virus codetections were investigated.

Results: PeV was detected in 1423 of 11 124 (12.8%) and 17 of 8100 (0.2%) stool and nasal swabs, respectively. Major genotypes among the 306 infection episodes identified were PeV-A1 (47.9%), PeV-A6 (20.1%), and PeV-A3 (18.3%). The incidence rate was 144 episodes (95% confidence interval, 128-160) per 100 child-years. First infections appeared at a median age of 8 (interquartile range, 6.0-11.7) months. Annual seasonal peaks changing from PeV-A1 to PeV-A3 were observed. Infection was positively associated with age ≥6 months, summer season, nonexclusive breastfeeding at age <3 months, and formal childcare attendance before age 12 months. Sole PeV infections were either asymptomatic (38.4%) or mild (32.7%), while codetection with other viruses in stool swabs was common (64.4%).

Conclusions: In contrast with hospital-based studies, this study showed that diverse and dynamically changing PeV genotypes circulate in the community causing mild or subclinical infections in children.Parechovirus can cause severe illnesses in children. However, studies focus mainly on hospitalized populations. True disease burden in the community remains largely unknown. From our community-based cohort, we found diverse parechovirus genotypes in the community, causing mild or subclinical infections in children.

Clinical trials registration: NCT01304914.

Keywords: clinical epidemiology; healthy children; longitudinal study; parechovirus; viral infection.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Submission of swabs, symptom diaries, human parechovirus detections, detection episodes, symptoms, and genotyping in the Observational Research in Childhood Infectious Diseases birth cohort. Abbreviations: AGE, acute gastroenteritis; ARI, acute respiratory infection; Ct, cycle threshold; ERV3, endogenous retrovirus 3; PeV-A, parechovirus A.
Figure 2.
Figure 2.
Phylogenetic analysis of VP3/1 sequences based on MUSCLE alignment of 255 sequences from the Observational Research in Childhood Infectious Diseases (ORChID) cohort with 58 GenBank reference sequences. ORChID sequences were depicted as filled triangles (▲) and GenBank reference sequences as circles (◯). The evolutionary relationships of taxa were inferred using the neighbor-joining method with bootstrap tests of 1000 replicates; only values ≥70% are shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the p-distance method and are in the units of the number of base differences per site. All ambiguous positions were removed for each sequence pair. A total of 289 positions were in the final dataset. Evolutionary analyses were conducted in MEGA6. Abbreviations: MUSCLE, MUltiple Sequence Comparison by Log- Expectation; ORChID, Observational Research in Childhood Infectious Diseases; PeV-A, parechovirus A.
Figure 3.
Figure 3.
Timing of first parechovirus A (PeV) infections by any PeVs and genotypes 1, 3, and 6. PeV first infections occurred in all age groups between 0 and 24 months (solid line), but 76.4% of the cohort had acquired their first infection before 12 months of age.
Figure 4.
Figure 4.
Seasonality of total episodes and episodes per enrolled child each month of all parechovirus A (PeV-A) genotypes as a function of enrolled subjects.

References

    1. Sharp J, Bell J, Harrison CJ, Nix WA, Oberste MS, Selvarangan R. Human parechovirus in respiratory specimens from children in Kansas City, Missouri. J Clin Microbiol 2012; 50:4111–3.
    1. Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L, Castellazzi L, Niesters HG. Pediatric parechovirus infections. J Clin Virol 2014; 60:84–9.
    1. Kadambari S, Harvala H, Simmonds P, Pollard AJ, Sadarangani M. Strategies to improve detection and management of human parechovirus infection in young infants. Lancet Infect Dis 2019; 19:e51–8.
    1. Harvala H, Robertson I, Chieochansin T, McWilliam Leitch EC, Templeton K, Simmonds P. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis 2009; 199:1753–60.
    1. Cumming G, Khatami A, McMullan BJ, et al. . Parechovirus genotype 3 outbreak among infants, New South Wales, Australia, 2013–2014. Emerg Infect Dis 2015; 21:1144–52.
    1. Olijve L, Jennings L, Walls T. Human parechovirus: an increasingly recognized cause of sepsis-like illness in young infants. Clin Microbiol Rev 2018; 31:e00047–17.
    1. Ferreras Antolin L, Kadambari S, Braccio S, et al. . Increased detection of human parechovirus infection in infants in England during 2016: epidemiology and clinical characteristics. Arch Dis Child 2018; 103:1061–6.
    1. Midgley CM, Jackson MA, Selvarangan R, et al. . Severe parechovirus 3 infections in young infants—Kansas and Missouri, 2014. J Pediatric Infect Dis Soc 2018; 7:104–12.
    1. Britton PN, Khandaker G, Khatami A, et al. . High prevalence of developmental concern amongst infants at 12 months following hospitalised parechovirus infection. J Paediatr Child Health 2018; 54:289–95.
    1. Westerhuis B, Kolehmainen P, Benschop K, et al. . Human parechovirus seroprevalence in Finland and the Netherlands. J Clin Virol 2013; 58:211–5.
    1. Watanabe K, Hirokawa C, Tazawa T. Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan. Epidemiol Infect 2016; 144:3451–60.
    1. Karelehto E, Brouwer L, Benschop K, et al. . Seroepidemiology of parechovirus A3 neutralizing antibodies, Australia, the Netherlands, and United States. Emerg Infect Dis 2019; 25:148–52.
    1. Tapia G, Cinek O, Witsø E, et al. . Longitudinal observation of parechovirus in stool samples from Norwegian infants. J Med Virol 2008; 80:1835–42.
    1. Tapia G, Cinek O, Rasmussen T, Grinde B, Stene LC, Rønningen KS. Longitudinal study of parechovirus infection in infancy and risk of repeated positivity for multiple islet autoantibodies: the MIDIA study. Pediatr Diabetes 2011; 12:58–62.
    1. Kolehmainen P, Oikarinen S, Koskiniemi M, et al. . Human parechoviruses are frequently detected in stool of healthy Finnish children. J Clin Virol 2012; 54:156–61.
    1. Morikawa S, Hiroi S, Kase T. Detection of respiratory viruses in gargle specimens of healthy children. J Clin Virol 2015; 64:59–63.
    1. Cristanziano VD, Bottcher S, Diedrich S, et al. . Detection and characterization of enteroviruses and parechoviruses in healthy people living in the south of Cote d’Ivoire. J Clin Virol 2015; 71:40–3.
    1. Moe N, Pedersen B, Nordbø SA, et al. . Respiratory virus detection and clinical diagnosis in children attending day care. PLoS One 2016; 11:e0159196.
    1. Joseph L, May M, Thomas M, et al. . Human parechovirus 3 in infants: expanding our knowledge of adverse outcomes. Pediatr Infect Dis J 2019; 38:1–5.
    1. Lambert SB, Ware RS, Cook AL, et al. . Observational research in childhood infectious diseases (ORChID): a dynamic birth cohort study. BMJ Open 2012; 2:e002134.
    1. Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The burden of community-managed acute respiratory infections in the first 2-years of life. Pediatr Pulmonol 2016; 51:1336–46.
    1. Sarna M, Lambert SB, Sloots TP, et al. . Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort. Thorax 2018; 73:969–79.
    1. Ye S, Whiley DM, Ware RS, Kirkwood CD, Lambert SB, Grimwood K. Multivalent rotavirus vaccine and wild-type rotavirus strain shedding in Australian infants: a birth cohort study. Clin Infect Dis 2018; 66:1411–8.
    1. Benschop K, Molenkamp R, van der Ham A, Wolthers K, Beld M. Rapid detection of human parechoviruses in clinical samples by real-time PCR. J Clin Virol 2008; 41:69–74.
    1. Harvala H, Robertson I, McWilliam Leitch EC, et al. . Epidemiology and clinical associations of human parechovirus respiratory infections. J Clin Microbiol 2008; 46:3446–53.
    1. Pham NT, Trinh QD, Khamrin P, et al. . Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol 2010; 48:115–9.
    1. Benschop K, Thomas X, Serpenti C, Molenkamp R, Wolthers K. High prevalence of human parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol 2008; 46:3965–70.
    1. Alexandersen S, Nelson TM, Hodge J, Druce J. Evolutionary and network analysis of virus sequences from infants infected with an Australian recombinant strain of human parechovirus type 3. Sci Rep 2017; 7:3861.
    1. McNeale D, Wang CYT, Arden KE, Mackay IM. HPeV-3 predominated among parechovirus A positive infants during an outbreak in 2013–2014 in Queensland, Australia. J Clin Virol 2018; 98:28–32.
    1. Tanaka S, Aoki Y, Matoba Y, et al. . Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014. Microbiol Immunol 2016; 60:854–8.
    1. Nielsen NM, Midgley SE, Nielsen AC, Christiansen CB, Fischer TK. Severe human parechovirus infections in infants and the role of older siblings. Am J Epidemiol 2016; 183:664–70.
    1. Karelehto E, Wildenbeest JG, Benschop KSM, et al. . Human parechovirus 1, 3 and 4 neutralizing antibodies in Dutch mothers and infants and their role in protection against disease. Pediatr Infect Dis J 2018; 37:1304–8.
    1. Aizawa Y, Yamanaka T, Watanabe K, Oishi T, Saitoh A. Asymptomatic children might transmit human parechovirus type 3 to neonates and young infants. J Clin Virol 2015; 70:105–8.
    1. Izumita R, Deuchi K, Aizawa Y, et al. . Intrafamilial transmission of parechovirus A and enteroviruses in neonates and young infants. J Pediatric Infect Dis Soc 2018. doi:10.1093/jpids/piy079.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren